Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T in Refractory Autoimmune Diseases
NCT06056921Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis (SSc) and 2 more, sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CD19 CAR-T cells infusion at 1 month, Maximum Tolerated Dose of CD19 CAR-T cells at 1 month and 5 more. Started Aug 2023; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromesystemic sclerosis (SSc)dermatomyositis (DM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06056921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056921.